Janus kinase inhibitors: An update on the progress and promise of targeted therapy in the myeloproliferative neoplasms

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 609-616

  Stein, Brady L ^a   Crispino, John D ^a   Moliterno, Alison R ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Janus family of tyrosine kinase inhibitors; myeloproliferative neoplasms; targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; CYT 387; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; JANUS KINASE 2; JANUS KINASE INHIBITOR; LESTAURTINIB; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLACEBO; RUXOLITINIB; SB 1518; TG 101348; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; AMINO ACID SUBSTITUTION; ANEMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ESSENTIAL THROMBOCYTOSIS; ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS; GENE MUTATION; GENETIC ASSOCIATION; HEADACHE; HUMAN; HYPERAMYLASEMIA; HYPERLIPASEMIA; HYPOTENSION; LEUKOPENIA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOCYTOSIS; VOMITING; WEIGHT GAIN;

ANIMALS; HUMANS; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS;

EID: 80054106619     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834d1b22     Document Type: Review

References (64)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-1061. (Pubitemid 40386783)
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-1790. (Pubitemid 40570926)
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397. (Pubitemid 40544655)
5. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
6. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24:1128-1138.
7. Stein BL, Moliterno AR. Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. JAMA 2010; 303:2513-2518.
8. Macdonald D, Cross NC. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. Pathobiology 2007; 74:81-88. (Pubitemid 46985280)
9. Verstovsek S, Tefferi A, editors. Myeloproliferative neoplasms. New York, New York: Springer; 2011.
10. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452-2466. (Pubitemid 44903749)
11. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112:2190-2198.
12. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wildtype Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111:3931-3940.
13. Pardanani A, Fridley BL, Lasho TL, et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008; 111:2785-2789.
14. Stein BL, WilliamsDM, Rogers O, et al. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617Fpositive myeloproliferative neoplasm patients. Exp Hematol 2011; 39:95-101.
15. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22:1299-1307.
16. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617VF mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110:840-846. (Pubitemid 47267419)
17. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21:1952-1959. (Pubitemid 47299969)
18. Silver RT, Vandris K, Wang YL, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011; 35:177-182.
19. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24:1574-1579.
20. Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 2009; 146:504-509.
21. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22:756-761. (Pubitemid 351559282)
22. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114:1477-1483.
23. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWGMRT). Blood 2006; 108:1497-1503. (Pubitemid 44316114)
24. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009; 113:4829-4833.
25. Mesa RA, Schwager S, Radia D, et al. The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009; 33:1199-1203.
26. Scherber R, Dueck A, Johansson PL, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): an international prospective validation trial in 402 patients. Blood ASH Annual Meeting Abstracts 2010; 116(21):4095.
27. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007; 109:68-76. (Pubitemid 46120195)
28. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895-2901.
29. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis: prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2010; 85:14-17.
30. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion- dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2011; 96:167-170.
31. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136:249-259. (Pubitemid 46020752)
32. Palandri F, Polverelli N, Catani L, et al. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 2011; 90:933-938.
33. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109:2310-2313. (Pubitemid 46425868)
34. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117:5857-5859.
35. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109:2446-2452. (Pubitemid 46425887)
36. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81:159-166. (Pubitemid 43205767)
37. Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138:354-358. (Pubitemid 47035399)
38. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93:1645-1651.
39. Barbui T, Thiele J, Passamonti F, et al. Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study on 1 104 patients. Blood ASH Annual Meeting Abstracts 2010; 116:457.
40. Gangat NC, Vaidya D, George R, et al. DIPSS-Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates karyotype, platelet count and transfusion status [abstract 4104]. Blood ASH Annual Meeting Abstracts 2010; 116:4104.
41. Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011. [Epub ahead of print]
42. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115:3109-3117.
43. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111:5663-5671.
44. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13:311-320. (Pubitemid 351446195)
45. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115:5232-5240.
46. Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23:1441-1445.
47. Verstovsek S, Odenike O, Scott B, et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood ASH Annual Meeting Abstracts 2009; 114:3905.
48. Verstovsek SMRG Jr, Levy RS, Gupta V, et al. Results of COMFORT-1, a randomized double-blind phase III trial of INCB18424 versus placebo for patients with myelofibrosis. J Clin Oncol 2011; 29(Suppl):abstract 6500.
49. Harrison CN, Kiladjian J, Al-Ali HK, et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis, postpolycythemia vera-myelofibrosis (PPV-MF), or postessential thrombocythemia-myelofibrosis (PET-MF). Journal of Clinical Oncology. 2011; 29(Suppl; abstract LBA6501).
50. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or postpolycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115:1131-1136.
51. Hexner E, Goldberg JD, Prchal JT, et al. A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis: a report on phase I A study of the Myeloproliferative Disorders Research Consortium (MPD-RC). Blood ASH Annual Meeting Abstracts 2009; 114:754.
52. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29:789-796.
53. Pardanani A, Caramazza D, George G, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol 2011; 29(Suppl; abstract 6514).
54. Deeg HJ, Odenike O, Scott BL, et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. J Clin Oncol 2011; 29(Suppl; abstract 6515).
55. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363:1117-1127.
56. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood ASH Annual Meeting Abstracts 2010; 116:313.
57. Moliterno AR, Hexner E, Roboz GJ, et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood ASH Annual Meeting Abstracts 2009; 114:753.
58. Begna K, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. Blood ASH Annual Meeting Abstracts 2010; 116:4109.
59. Vannucchi AM, Guglielmelli P, Lupo L, et al. A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results. Blood ASH Annual Meeting Abstracts 2010; 116:314.
60. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112:3065-3072.
61. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27:5418-5424.
62. Ianotto J-C, Boyer-Perrard F, Demory J-L, et al. Efficacy and safety of Peginterferon-{ alpha}2a in myelofibrosis: a study of the FIM and GEM French Cooperative Groups. Blood ASH Annual Meeting Abstracts 2010; 116:4103.
63. Quintas-Cardama A, Levine R, Manshouri T, et al. High rates of molecular response after long-term follow-up of patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV) treated with pegylated interferon-alfa-2A (PEG-IFN-{alpha}-2A; PEGASYS). Blood ASH Annual Meeting Abstracts 2010; 116:461.
64. DeAngelo DJ, Tefferi A, Fiskus W, et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood ASH Annual Meeting Abstracts 2010; 116:630.